Oxford Immunotec is set to return to private ownership in a $591m acquisition deal.
Oxford Immunotec, a US-listed immunology diagnostics assay producer spun out of University of Oxford, has agreed to be acquired by life sciences, environmental and industrial technology and services provider Perkin Elmer.
Perkin Elmer will pay $22 for each outstanding Oxford Immunotec share, a premium of around 28.3% on its closing price on January 5, valuing the spinout’s total issued and pending equity at $591m.
Founded in 2001, Oxford Immunotec provides research assay kits that measure the immune system’s…
